AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8865828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation via nasal prongs
Number of subjects: 289
Study 8865828 — intervention group
Group type: COMPARATOR
Intervention: No oxygen supplementation
Number of subjects: 289
Study 1555329 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.400 mg)
Number of subjects: 21
Study 1555329 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium (He) + Oxygen (O2) breathing
Number of subjects: 21
Study 1555329 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol after equilibration with He + O2
Number of subjects: 21
Study 3157318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 3157318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben
Number of subjects: 0
Study 3157318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30241564 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive message (reciprocity)
Number of subjects: 1085322
Study 30241564 — intervention group
Group type: COMPARATOR
Intervention: Control prompt
Number of subjects: 1085322
Study 30241564 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 1085322
Study 30241564 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms message plus image
Number of subjects: 1085322
Study 26523836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (hydroxyurea)
Number of subjects: 121
Study 26523836 — intervention group
Group type: COMPARATOR
Intervention: Chronic transfusion therapy
Number of subjects: 121
Study 26523836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 121
Study 25154195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tone power therapy for 60 minutes for 15 days
Number of subjects: 20
Study 25154195 — intervention group
Group type: COMPARATOR
Intervention: Kinesis exercises for 15 days
Number of subjects: 20
Study 22236402 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals varying in type and amount of fat
Number of subjects: 20
Study 20820117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanhujori facilities
Number of subjects: 55
Study 20820117 — intervention group
Group type: COMPARATOR
Intervention: Not using Sanhujori facilities
Number of subjects: 55
Study 18258342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alanyl-Gln dipeptide (AG) supplementation (0.5 g/kg/day)
Number of subjects: 44
Study 18258342 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral alanyl-Gln dipeptide (AG) supplementation (0.32±0.02 g/kg/day)
Number of subjects: 44
Study 18258342 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gln-free tube feedings)
Number of subjects: 44
Study 15723741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) group, receiving 3 to 5 mL of breast milk every hour through a nasogastric feeding tube, starting a mean of 12 h after surgery
Number of subjects: 56
Study 15723741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) group
Number of subjects: 56
Study 15723741 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 56
Study 14607208 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 50 mg t.i.d. for 6 months
Number of subjects: 0
Study 10808175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40 mg/day) for 9 days
Number of subjects: 0
Study 10808175 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 9014715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin and Ringer's acetate
Number of subjects: 198
Study 9014715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin and dextran
Number of subjects: 198
Study 9014715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran and Ringer's acetate
Number of subjects: 198
Study 9014715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran and dextran
Number of subjects: 198
Study 1325348 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine 800 mg/d for 10 days
Number of subjects: 9
Study 1325348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6617682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg daily
Number of subjects: 529
Study 6617682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 6617682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (for patients starting therapy later than 5 days after myocardial infarction)
Number of subjects: 529
Study 6617682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (for patients starting therapy after 12 days)
Number of subjects: 529
Study 6617682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (for patients on digitalis therapy)
Number of subjects: 529
Study 31377050 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative voices
Number of subjects: 84
Study 31377050 — intervention group
Group type: COMPARATOR
Intervention: Neutral voices
Number of subjects: 84
Study 31377050 — intervention group
Group type: COMPARATOR
Intervention: Non-voice ambient sounds
Number of subjects: 84
Study 31377050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful voice-appraisals
Number of subjects: 84
Study 30985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 65
Study 30985536 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block
Number of subjects: 65
Study 30985536 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor surgical conditions
Number of subjects: 65
Study 30517164 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisory message in the EMR during diabetes consultations
Number of subjects: 2778
Study 30517164 — intervention group
Group type: COMPARATOR
Intervention: Standard care without advisory message
Number of subjects: 2778
Study 26897364 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Services Use Self‐Efficacy (PRESS) Scale
Number of subjects: 242
Study 26897364 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESS Scale
Number of subjects: 242
Study 24752608 — intervention group
Group type: EXPERIMENTAL
Intervention: In-motion device (Soprano XL 810 nm diode laser in SHR mode)
Number of subjects: 0
Study 24752608 — intervention group
Group type: COMPARATOR
Intervention: Single pass device (LightSheer Duet 810 nm diode laser)
Number of subjects: 0
Study 22324753 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and Balance Group (SBG; n = 63)
Number of subjects: 280
Study 22324753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness Group (FG; n = 64)
Number of subjects: 280
Study 22324753 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n = 80)
Number of subjects: 280
Study 22324753 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted Group (MG; n = 73)
Number of subjects: 280
Study 20307165 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 93
Study 20307165 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 18929280 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 7.5 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 50
Study 18929280 — intervention group
Group type: COMPARATOR
Intervention: Combined sciatic-femoral nerve blocks using a mixture of 20 mL of lidocaine 2% plus 20 mL of bupivacaine 0.5%
Number of subjects: 50
Study 15693870 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 200 U/kg twice a week, subcutaneously for 6 weeks
Number of subjects: 292
Study 15693870 — intervention group
Group type: COMPARATOR
Intervention: Control group (150 premature infants receiving conventional supportive therapy)
Number of subjects: 292
Study 12390617 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal prochlorperazine (PCZ) 3 mg
Number of subjects: 114
Study 12390617 — intervention group
Group type: COMPARATOR
Intervention: Buccal placebo
Number of subjects: 114
Study 12390617 — intervention group
Group type: COMPARATOR
Intervention: Oral ergotamine tartarate (ERG) 1 mg plus caffeine 100 mg
Number of subjects: 114
Study 12390617 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 114
Study 10100056 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release nifedipine
Number of subjects: 14
Study 10100056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7598922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam (Group 2)
Number of subjects: 58
Study 7598922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam and supplemental oxygen (Group 3)
Number of subjects: 58
Study 7598922 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy alone (Group 1)
Number of subjects: 58
Study 2640173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of water
Number of subjects: 0
Study 2640173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of barium
Number of subjects: 0
Study 2640173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of Coca-Cola
Number of subjects: 0
Study 30850957 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P16 5 mg/kg
Number of subjects: 144
Study 30850957 — intervention group
Group type: COMPARATOR
Intervention: EU-bevacizumab 5 mg/kg
Number of subjects: 144
Study 30850957 — intervention group
Group type: COMPARATOR
Intervention: US-bevacizumab 5 mg/kg
Number of subjects: 144
Study 25600659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1110 MBq I‐131 (low dose)
Number of subjects: 115
Study 25600659 — intervention group
Group type: COMPARATOR
Intervention: 3700 MBq I‐131 (standard dose)
Number of subjects: 115
Study 25160859 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat & Observe (T&O) regimen
Number of subjects: 93
Study 25160859 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait & Extend (W&E) regimen
Number of subjects: 93
Study 23457562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified counselling on physical activity, diet, and appropriate weight gain
Number of subjects: 399
Study 23457562 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 399
Study 21296315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 29
Study 21296315 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 29
Study 18081558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic therapy with luteinising hormone‐releasing hormone, thyroid‐releasing hormone, corticotrophin‐releasing hormone and arginine hydrochloride
Number of subjects: 10
Study 18081558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic therapy
Number of subjects: 10
Study 17319338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous diclofenac (1 mg/kg i.v. after induction followed by an infusion of 1 mg/kg over 2 hours)
Number of subjects: 150
Study 17319338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 150
Study 12728374 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted resection
Number of subjects: 40
Study 12728374 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 40
Study 10886272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (10‐20 mg three times a week for 2 months)
Number of subjects: 60
Study 10886272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral isotretinoin)
Number of subjects: 60
Study 8888671 — intervention group
Group type: EXPERIMENTAL
Intervention: Training paradigm for clinical investigators
Number of subjects: 0
Study 1401445 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched metal RBBs (E-bridges)
Number of subjects: 203
Study 1401445 — intervention group
Group type: COMPARATOR
Intervention: Perforated RBBs (P-bridges)
Number of subjects: 203
Study 1401445 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil F cementation with E-bridges
Number of subjects: 203
Study 1401445 — intervention group
Group type: COMPARATOR
Intervention: Maxillary anterior RBBs
Number of subjects: 203
Study 1401445 — intervention group
Group type: COMPARATOR
Intervention: Anterior RBBs
Number of subjects: 203
Study 1401445 — intervention group
Group type: COMPARATOR
Intervention: Posterior RBBs
Number of subjects: 203
Study 3926169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadexomer iodine (Iodosorb)
Number of subjects: 61
Study 3926169 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 61
Study 31375842 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger Appalachians
Number of subjects: 905
Study 31375842 — intervention group
Group type: COMPARATOR
Intervention: Older Appalachians
Number of subjects: 905
Study 29739264 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific positioning guides (PSPGs)
Number of subjects: 40
Study 29739264 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 40
Study 26963599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikram Yoga practice
Number of subjects: 52
Study 26963599 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study 24463131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 60
Study 24463131 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study 22582690 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic fields (30 min exposure)
Number of subjects: 37
Study 22582690 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 37
Study 20926506 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene©, an orally active, gamma selective retinoid agonist
Number of subjects: 0
Study 20926506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18273733 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (Lantus) daily from start of surgery
Number of subjects: 43
Study 18273733 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (Actrapid) when needed (sliding scale)
Number of subjects: 43
Study 16086938 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14703
Study 16086938 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14703
Study 16086938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (valsartan and captopril)
Number of subjects: 14703
Study 12170023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of methylprednisolone (10 mg/kg body weight) 30 minutes before surgery (MP group)
Number of subjects: 66
Study 12170023 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (control group)
Number of subjects: 66
Study 12170023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of methylprednisolone (MP group)
Number of subjects: 66
Study 10093840 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty (PTA) alone
Number of subjects: 62
Study 10093840 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty followed by implantation of Palmaz stents
Number of subjects: 62
Study 8643415 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM) patients
Number of subjects: 58
Study 8643415 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched subjects (control group)
Number of subjects: 58
Study 1976147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched (33% oxygen)
Number of subjects: 20
Study 1976147 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-dioxide-enriched (3% carbon dioxide)
Number of subjects: 20
Study 1976147 — intervention group
Group type: COMPARATOR
Intervention: Normal compressed air
Number of subjects: 20
Study 7222702 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 43
Study 7222702 — intervention group
Group type: EXPERIMENTAL
Intervention: prodipine
Number of subjects: 43
Study 7222702 — intervention group
Group type: EXPERIMENTAL
Intervention: amantadine
Number of subjects: 43
Study 30498987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 50
Study 30498987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical-behavior therapy (DBT)
Number of subjects: 50
Study 30498987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) or Dialectical-behavior therapy (DBT)
Number of subjects: 50
Study 30878190 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Number of subjects: 32
Study 30878190 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group
Number of subjects: 32
Study 28510730 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 252
Study 28510730 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 252
Study 25377933 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3207 (20 mg dose)
Number of subjects: 0
Study 25377933 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3207 (40-100 mg dose)
Number of subjects: 0
Study 25377933 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP receptor antagonists
Number of subjects: 0
Study 23728118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription chart design from NHS Highland
Number of subjects: 72
Study 23728118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription chart design from NHS Grampian
Number of subjects: 72
Study 23728118 — intervention group
Group type: COMPARATOR
Intervention: Other three prescription chart designs
Number of subjects: 72
Study 23728118 — intervention group
Group type: EXPERIMENTAL
Intervention: Time taken to complete prescriptions
Number of subjects: 72
Study 23728118 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity with a chart
Number of subjects: 72
Study 21345844 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐15 concentrations above the median on admission
Number of subjects: 238
Study 21345844 — intervention group
Group type: COMPARATOR
Intervention: Myocardial salvage
Number of subjects: 238
Study 19268392 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental anxiety induction
Number of subjects: 149
Study 19268392 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 16171630 — intervention group
Group type: EXPERIMENTAL
Intervention: IA tramadol 50 mg
Number of subjects: 75
Study 16171630 — intervention group
Group type: EXPERIMENTAL
Intervention: IA morphine 5 mg
Number of subjects: 75
Study 16171630 — intervention group
Group type: COMPARATOR
Intervention: IA normal saline (control group)
Number of subjects: 75
Study 11911025 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained nurse case managers
Number of subjects: 101
Study 11911025 — intervention group
Group type: COMPARATOR
Intervention: Untrained nurse case managers
Number of subjects: 101
Study 10421669 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) 15 mcg for 12 months
Number of subjects: 467
Study 10421669 — intervention group
Group type: COMPARATOR
Intervention: Initial interferon treatment (either 9 mcg CIFN or 3 MU IFN-alpha2b 3 times per week)
Number of subjects: 467
Study 7671894 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3 months, exercising on a bicycle ergometer for 30 min three times a week at 50-60% of peak oxygen consumption)
Number of subjects: 20
Study 7671894 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 20
Study 7671894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 20
Study 7671894 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 2210807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol beer (reduced from 537 to 57 ml/week)
Number of subjects: 63
Study 2210807 — intervention group
Group type: COMPARATOR
Intervention: Normal alcohol intake (543 to 557 ml/week)
Number of subjects: 63
Study 2210807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet with placebo sodium chloride tablets
Number of subjects: 63
Study 2210807 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake with 100 mmol/day sodium chloride tablets
Number of subjects: 63
Study 6252180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1.0 to 1.5 mg/kg
Number of subjects: 26
Study 6252180 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 0.75 mg/kg
Number of subjects: 26
Study 6252180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1.0 to 1.5 mg/kg + Amikacin 0.75 mg/kg
Number of subjects: 26
Study 6252180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 15 mg/kg
Number of subjects: 26
Study 6252180 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg
Number of subjects: 26
Study 6252180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 15 mg/kg + Amikacin 15 mg/kg
Number of subjects: 26
Study 31828841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rehydration (intravenous fluid over six hours)
Number of subjects: 208
Study 31828841 — intervention group
Group type: COMPARATOR
Intervention: Slow rehydration (intravenous fluid over 12 hours)
Number of subjects: 208
Study 31828841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rehydration
Number of subjects: 208
Study 31828841 — intervention group
Group type: COMPARATOR
Intervention: Slow rehydration
Number of subjects: 208
Study 31828841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 208
Study 30678465 — intervention group
Group type: EXPERIMENTAL
Intervention: n3PUFA (4 g/d)
Number of subjects: 98
Study 30678465 — intervention group
Group type: COMPARATOR
Intervention: Soy oil control
Number of subjects: 98
Study 28520849 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (BB)
Number of subjects: 1144
Study 28520849 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (BB) after enrolment
Number of subjects: 1144
Study 28520849 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (BB) in TNBC subset
Number of subjects: 1144
Study 25872612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task functional power training (DT-FPT)
Number of subjects: 280
Study 25872612 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 280